The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.
Ensoli
Barbara
B
National AIDS Center, Istituto Superiore di Sanità, Rome, Italy. barbara.ensoli@iss.it
Fiorelli
Valeria
V
Ensoli
Fabrizio
F
Lazzarin
Adriano
A
Visintini
Raffaele
R
Narciso
Pasquale
P
Di Carlo
Aldo
A
Monini
Paolo
P
Magnani
Mauro
M
Garaci
Enrico
E
D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology; D018791:CD4 Lymphocyte Count; D004311:Double-Blind Method; D015483:HIV Antibodies / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology; D019562:Viral Load; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000009:adverse effects* / Q000276:immunology
D016915:AIDS Vaccines; D015483:HIV Antibodies; D011994:Recombinant Proteins; D054322:tat Gene Products, Human Immunodeficiency Virus